Back to Results

Sutro Biopharma (STRO)

Sutro Biopharma, Inc. is a biotechnology company focused on oncology. The company is developing antibody-drug conjugate programs using its cell-free protein synthesis and site-specific conjugation platforms, including XpressCF and XpressCF+. Its pipeline includes STRO-004, which is being studied for solid tumors that express tissue factor, and STRO-003, an ADC aimed at ROR1-related cancers in both solid and blood malignancies. Sutro Biopharma is also advancing VAX-24 and VAX-31, pneumococcal vaccine candidates in late-stage clinical development. In addition to its internal programs, the company has collaboration and license agreements with Vaxcyte, Tasly Biopharmaceuticals, Ipsen, and Astellas Pharma. Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma trades on the NASDAQ under the symbol STRO.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-STRO
$17.13
6.2% Upside
Fair
$47.23
192.8% Upside
Bargain
Weak
0.0%
November 11, 2026
5.9x
267.5 M
113.9 M
3.8%
64.9%
-8.3
80.6%
Valuation • Fair Value

Sutro Biopharma (NASDAQ-STRO) Fair Value by Valuation Model

Review the available estimates for Sutro Biopharma (NASDAQ-STRO), including EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$17.13

Estimated upside of 6.2% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

EPV Fair Value

$20.76

Earnings power value estimate.

Comps Fair Value

$16.52

Comparable-company valuation reference.

Analyst Price Target

$47.23

Analysts imply upside of 192.8%.

How to read these valuation models

Use the 5 available valuation references for Sutro Biopharma (NASDAQ-STRO) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Sutro Biopharma (NASDAQ-STRO)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

45.702 M

Current operating scale indicator.

Revenue Forecast

44.817 M

Forward revenue estimate.

EBITDA

-125.8 M

Current operating profitability reference.

EBITDA Forecast

-99.514 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Sutro Biopharma (NASDAQ-STRO) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Sutro Biopharma (NASDAQ-STRO)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

3

Weak quality score that deserves closer review.

Beneish M-Score

-2.78

No elevated caution signal from this screen.

Altman Z-Score

-8.3

Lower score that deserves closer risk review.

FCF / Net Income

80.6%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Sutro Biopharma (NASDAQ-STRO). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Sutro Biopharma (NASDAQ-STRO)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 11, 2026

Days to Earnings

50

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Sutro Biopharma (NASDAQ-STRO), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Sutro Biopharma (NASDAQ-STRO) Stock Forecast & Technical Outlook

Review Sutro Biopharma (NASDAQ-STRO) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Sutro Biopharma (NASDAQ-STRO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for Sutro Biopharma (NASDAQ-STRO) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Sutro Biopharma (NASDAQ-STRO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Sutro Biopharma (NASDAQ-STRO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Sutro Biopharma (NASDAQ-STRO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Sutro Biopharma (NASDAQ-STRO)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Sutro Biopharma (NASDAQ-STRO) has a Strong Buy consensus, with 10 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 10
Hold 0
Sell 0
FAQ • Fast Investor Answers

Sutro Biopharma (NASDAQ-STRO) Stock FAQ

Data-supported answers about Sutro Biopharma (NASDAQ-STRO), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$17.13
Estimated upside 6.2%
Valuation Rating
Undervalued
Estimated upside of 6.2%
Analyst Target
$47.23
Implied upside 192.8%
Financial Health
Weak
Current financial-health read

The current fair value estimate for Sutro Biopharma (NASDAQ-STRO) is $17.13. This implies an estimated upside of 6.2% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 6.2% versus the current market price.

The available analyst price target for Sutro Biopharma (NASDAQ-STRO) is $47.23. The analyst target implies estimated upside of 192.8%.

The current financial health read for Sutro Biopharma (NASDAQ-STRO) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Sutro Biopharma (NASDAQ-STRO) is November 11, 2026.

The latest available data indicates no current dividend yield for Sutro Biopharma (NASDAQ-STRO).

The current market capitalization listed for Sutro Biopharma is 267.5 M.

The current enterprise value listed for Sutro Biopharma is 113.9 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Sutro Biopharma is NASDAQ-STRO, and the stock is listed on NASDAQ.

Sutro Biopharma (NASDAQ-STRO) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Sutro Biopharma is 3.8%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Sutro Biopharma is 64.9%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 468.7 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 221.8 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 189.3 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 130.5 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 80.273 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 72.885 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 61.249 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 56.346 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 41.851 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 41.337 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 33.673 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 33.298 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 27.607 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.385 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.728 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 25.339 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.342 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.853 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.602 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.46 B